Methods and compositions for detecting tau pathology are described. The compositions for detecting tau pathology comprise a targeting ligand that specifically binds to a cell surface marker of tau pathology, wherein the targeting ligand is linked to a liposome that includes an imaging agent. The compositions can be used in a method for imaging tau pathology in a subject that comprises administering to the subject an effective amount of the composition to a subject and imaging at least a portion of the subject to determine if that portion of the subject exhibits tau pathology. The compositions can also be used to detect tau pathology in biological samples obtained from a subject.

Polynucleotides, such as aptamers, comprising at least first one 5-position modified pyrimidine and at least one second 5-position modified pyrimidine are provided, wherein the first and second 5-position modified pyrimidines are different. Methods of selecting and using such polynucleotides, such as aptamers, are also provided.

The present disclosure generally relates to aptamers and, more specifically, to fluoroarabino nucleic acid (FANA) aptamers, that bind to the SARS-CoV-2 receptor binding domain (spike (“S”) protein) and thereby block binding to the angiotensin-converting enzyme 2 (ACE2) host cellular receptor. Such FANA aptamers have many applications including their use as antiviral drugs for treatment and prevention of diseases, such as COVID-19, resulting from SARS-CoV-2 infection.

The present disclosure relates to aptamers, polynucleotides, and nuclei acid molecules, which include a polynucleotide sequence capable of specifically binding polypeptides participating in M. hyopneumoniae infection. Also provided are methods of using nucleic acid molecules, polynucleotides and synthetic antibodies directed there against for detection, treating and neutralization of M. hyopneumoniae infection.

The present invention provides an aptamer that specifically hinds CD44, composition comprising the aptamer, as well as methods for detecting CD44 and for targeted delivery to CD44-expressing cells.

The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.

The invention relates to a process for selecting aptamers substrates of one helicase enzyme, comprising the implementation of a helicase SELEX process comprising several cycles, wherein each cycle comprises the following steps: a) Providing a library of nucleic acid duplex constructs comprising one nucleic acid strand containing a random sequence of 10 to 100 nucleotides framed by fixed sequences at each end; b) Incubation of said library with said helicase in appropriate conditions for the dissociation of certain duplex constructs by the helicase, resulting in release of the aptamers substrates of the helicase; c) Isolation and amplification of said aptamers substrates of the helicase; d) Creation of a novel library of nucleic acid duplex constructs enriched in duplex constructs comprising aptamers substrates of the helicase.

The present invention relates to aptamers, polynucleotides, and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding polypeptides participating in M. hyopneumoniae infection. Also provided are methods of using nucleic acid molecules, polynucleotides and synthetic antibodies directed there against for detection, treating and neutralization of M. hyopneumoniae infection.

The invention relates to mutant DNA polymerases of the Pol theta subfamily capable of performing non-templated nucleic acid extension, or of a functional fragment of such a polymerase, methods of producing these mutant DNA polymerases, kits and methods of using these mutant DNA polymerases.

The present invention relates to an aptamer screening method, and the aptamer screened by the screening method of the present invention binds to a site other than a site where the antibody binds to the target substance to be applicable in various fields such as sandwich-type biosensors and reduce a significant time without requiring a separate pairing selection process. In addition, such an aptamer has excellent stability and sensitivity compared to conventional preparations comprising an antibody, can be mass-produced at low cost in a short time by a chemical synthesis method, and is easily transformed in various ways to increase a binding force. In addition, the immunoassay method using the aptamer screened by the aptamer screening method of the present invention selectively amplifies only the aptamer binding to the target substance in a heterogeneous sandwich structure to detect a relative fluorescence signal, thereby detecting the target substance sensitively and quickly.